compared to vehicle treated fAD tissue (Fig 3B). This reduction was particularly evident in the in 90-day-old fAD organoids treated for 60-days (Fig 3C). In contrast to the dramatic reduction of Aβ aggregation with compound treatment, immunoreactivity for pTau was unaffected following 30 days of treatment compared to vehicle-treated controls (Fig 3D). However, following 60 days of treatment, the 90 day-old organoids showed significantly less pTau immunoreactivity compared to vehicle-treated controls in dose dependent manner (Fig 3D). These results indicate that specific AD-like phenotypes observed in patient iPSC-derived organoids can be ameliorated with drug treatment, suggesting that this system is amenable to compound testing.
